{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&q=relapsed+refractory+myeloma", "query": { "q": "relapsed refractory myeloma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&q=relapsed+refractory+myeloma&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T08:09:10.375Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03575325", "title": "Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoid Leukemia", "Acute Lymphoblastic Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Relapsed Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "CPX-351", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2018-10-11", "completion_date": "2023-09-14", "has_results": true, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-07-24T08:09:10.375Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03575325" }, { "nct_id": "NCT05205252", "title": "A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Hematologic Malignancy", "Refractory Hematologic Malignancy" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Daratumumab (Intravenously)", "type": "DRUG" }, { "name": "Mosunetuzumab", "type": "DRUG" }, { "name": "Daratumumab (Subcutaneously)", "type": "DRUG" }, { "name": "Hyaluronidase-Fihj", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone 20mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-12-22", "completion_date": "2023-07-05", "has_results": false, "last_update_posted_date": "2023-08-15", "last_synced_at": "2026-07-24T08:09:10.375Z", "location_count": 3, "location_summary": "Santa Fe, California • Bolivar, Missouri • East Brunswick, New Jersey", "locations": [ { "city": "Santa Fe", "state": "California" }, { "city": "Bolivar", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05205252" }, { "nct_id": "NCT03642626", "title": "MT2017-45: CAR-T Cell Therapy for Heme Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Large B-cell Lymphoma" ], "interventions": [ { "name": "KYMRIAH", "type": "DRUG" }, { "name": "YESCARTA", "type": "DRUG" }, { "name": "Fludarabine 30mg/m2 4 doses", "type": "DRUG" }, { "name": "Cyclophosphamide 500 mg/m2; 2 doses", "type": "DRUG" }, { "name": "Fludarabine 30mg/m2 3 doses", "type": "DRUG" }, { "name": "Cyclophosphamide 500 mg/m2; 3 doses", "type": "DRUG" }, { "name": "Fludarabine 25mg/m2 3 days", "type": "DRUG" }, { "name": "Cyclophosphamide 250 mg/m2; 3 days", "type": "DRUG" }, { "name": "Tecartus", "type": "DRUG" }, { "name": "Abecma, Intravenous Suspension", "type": "DRUG" }, { "name": "Cyclophosphamide 900 mg/m2; 1 day", "type": "DRUG" }, { "name": "Breyanzi Injectable Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 150, "start_date": "2018-12-18", "completion_date": "2028-06-01", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-07-24T08:09:10.375Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03642626" }, { "nct_id": "NCT03777410", "title": "Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma in Relapse" ], "interventions": [], "intervention_types": [], "sponsor": "Travera Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2019-02-11", "completion_date": "2024-06-30", "has_results": false, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-07-24T08:09:10.375Z", "location_count": 4, "location_summary": "Duarte, California • Boston, Massachusetts • New York, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03777410" }, { "nct_id": "NCT02948283", "title": "Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anemia", "Fatigue", "Fever", "Lymphadenopathy", "Lymphocytosis", "Night Sweats", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Plasma Cell Myeloma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Plasma Cell Myeloma", "Splenomegaly", "Thrombocytopenia", "Weight Loss" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Metformin Hydrochloride", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Quality-of-Life", "type": "OTHER" }, { "name": "Questionnaire", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-09-05", "completion_date": "2017-12-01", "has_results": false, "last_update_posted_date": "2021-02-12", "last_synced_at": "2026-07-24T08:09:10.375Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02948283" }, { "nct_id": "NCT02765854", "title": "Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2016-09-01", "completion_date": "2023-05-23", "has_results": true, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-07-24T08:09:10.375Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Ann Arbor, Michigan • St Louis, Missouri", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02765854" }, { "nct_id": "NCT00083473", "title": "A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Chronic", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "Pivanex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Titan Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2004-05", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2005-08-30", "last_synced_at": "2026-07-24T08:09:10.375Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083473" }, { "nct_id": "NCT02109224", "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult B Acute Lymphoblastic Leukemia", "Chronic Lymphocytic Leukemia", "Cutaneous B-Cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "HIV Infection", "Intraocular Lymphoma", "Multicentric Angiofollicular Lymphoid Hyperplasia", "Nodal Marginal Zone Lymphoma", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Plasma Cell Myeloma", "Small Intestinal Lymphoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2014-09", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-08-20", "last_synced_at": "2026-07-24T08:09:10.375Z", "location_count": 7, "location_summary": "Los Angeles, California • Baltimore, Maryland • St Louis, Missouri + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02109224" }, { "nct_id": "NCT05172596", "title": "PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "PHE885", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 146, "start_date": "2022-03-03", "completion_date": "2025-05-21", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-07-24T08:09:10.375Z", "location_count": 6, "location_summary": "Palo Alto, California • Atlanta, Georgia • Boston, Massachusetts + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05172596" }, { "nct_id": "NCT05391750", "title": "Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2022-10-19", "completion_date": "2028-02-12", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-07-24T08:09:10.375Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05391750" } ] }